M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Halozyme Therapeutics, Inc. to acquire Elektrofi
Announced Oct 1, 2025 · Closed · Private target
Deal value$50M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationNot disclosed
Transaction
- Acquirer
- Halozyme Therapeutics, Inc. (HALO)
- Target
- Elektrofi
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- BofA Securities
- To the target
- Centerview
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)